Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.
Ami N ShahLisa FlaumIrene HelenowskiCesar A Santa-MariaSarika JainAlfred RademakerValerie NelsonDean TsarwhasMassimo CristofanilliWilliam GradisharPublished in: Journal for immunotherapy of cancer (2020)
NCT03044730.